Page 17 - Trials Network News Today

The clinical value of bamlanivimab for hospitalized COVID-19 patients depends on whether patients have endogenous neutralizing antibodies at the time of treatment.

DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) — Data from the HIV Prevention Trials Network (HPTN) studies HPTN 083 and HPTN 084 helped provide important…

Approval marks pivotal expansion of HIV prevention options in the United States.

DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Data from the HIV Prevention Trials Network (HPTN) studies HPTN 083 and HPTN 084 helped provide important information for yesterday's decision by the U.S.

Investegate announcements from HIV Prevention Trials Network, HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention

Yesterday the U.S. Food and Drug Administration announced its first approval of a long-acting HIV prevention medication. Developed by ViiV Healthcare

HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention GlobeNewswire December 21, 2021 DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Data from the HIV Prevention Trials Network (HPTN) studies HPTN 083 and HPTN 084 helped provide important information for yesterday’s decision by the U.S. Food and...

The new research, led by the University of Sydney, is a two-year follow up of the Australian Placental Transfusion Study, the award-winning and largest-ever clinical trial of delayed cord clamping of babies born before 30 weeks. It was conducted in 2

40 years of AIDS vaccine research - IAVI. A timeline of major milestones in the decades-long effort to develop an HIV vaccine.

A highly anticipated clinical trial in eight sub-Saharan countries is the first to specifically evaluate the efficacy of a COVID-19 vaccine in people living with HIV, including those with poorly controlled infections.